Tumor cells are dependent on a practical ubiquitin-proteasome technique, rendering it a lovely focus on for the development of most cancers therapeutics. Medication that inhibit the DUB exercise of the 19S proteasome can perhaps be used as second line therapy for sufferers that don't respond to